Surface-immobilized aptamers for cancer cell isolation and microscopic cytology

Yuan Wan, Young Tae Kim, Na Li, Steve K. Cho, Robert Bachoo, Andrew D. Ellington, Samir M. Iqbal

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Exposing rare but highly malignant tumor cells that migrate from the primary tumor mass into adjacent tissue(s) or circulate in the bloodstream is critical for early detection and effective intervention(s). Here, we report on an aptamer-based strategy directed against epidermal growth factor receptor (EGFR), the most common oncogene in glioblastoma (GBM), to detect these deadly tumor cells. GBMs are characterized by diffuse infiltration into normal brain regions, and the inability to detect GBM cells renders the disease surgically incurable with a median survival of just 14.2 months. To test the sensitivity and specificity of our platform, anti-EGFR RNA aptamers were immobilized on chemically modified glass surfaces. Cells tested included primary human GBM cells expressing high levels of the wild-type EGFR, as well as genetically engineered murine glioma cells overexpressing the most common EGFR mutant (EGFRvIII lacking exons 2-7) in Ink4a/Arf-deficient astrocytes. We found that surfaces functionalized with anti-EGFR aptamers could capture both the human and murine GBM cells with high sensitivity and specificity. Our findings show how novel aptamer substrates could be used to determine whether surgical resection margins are free of tumor cells, or more widely for detecting tumor cells circulating in peripheral blood to improve early detection and/or monitoring residual disease after treatment.

Original languageEnglish (US)
Pages (from-to)9371-9380
Number of pages10
JournalCancer Research
Volume70
Issue number22
DOIs
StatePublished - Nov 15 2010

Fingerprint

Cell Separation
Cell Biology
Epidermal Growth Factor Receptor
Glioblastoma
Neoplasms
Nucleotide Aptamers
Circulating Neoplastic Cells
Sensitivity and Specificity
Oncogenes
Glioma
Astrocytes
Glass
Exons
Survival
Brain

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Wan, Y., Kim, Y. T., Li, N., Cho, S. K., Bachoo, R., Ellington, A. D., & Iqbal, S. M. (2010). Surface-immobilized aptamers for cancer cell isolation and microscopic cytology. Cancer Research, 70(22), 9371-9380. https://doi.org/10.1158/0008-5472.CAN-10-0568

Surface-immobilized aptamers for cancer cell isolation and microscopic cytology. / Wan, Yuan; Kim, Young Tae; Li, Na; Cho, Steve K.; Bachoo, Robert; Ellington, Andrew D.; Iqbal, Samir M.

In: Cancer Research, Vol. 70, No. 22, 15.11.2010, p. 9371-9380.

Research output: Contribution to journalArticle

Wan, Y, Kim, YT, Li, N, Cho, SK, Bachoo, R, Ellington, AD & Iqbal, SM 2010, 'Surface-immobilized aptamers for cancer cell isolation and microscopic cytology', Cancer Research, vol. 70, no. 22, pp. 9371-9380. https://doi.org/10.1158/0008-5472.CAN-10-0568
Wan, Yuan ; Kim, Young Tae ; Li, Na ; Cho, Steve K. ; Bachoo, Robert ; Ellington, Andrew D. ; Iqbal, Samir M. / Surface-immobilized aptamers for cancer cell isolation and microscopic cytology. In: Cancer Research. 2010 ; Vol. 70, No. 22. pp. 9371-9380.
@article{3085765860524c55877d5a36c2be6213,
title = "Surface-immobilized aptamers for cancer cell isolation and microscopic cytology",
abstract = "Exposing rare but highly malignant tumor cells that migrate from the primary tumor mass into adjacent tissue(s) or circulate in the bloodstream is critical for early detection and effective intervention(s). Here, we report on an aptamer-based strategy directed against epidermal growth factor receptor (EGFR), the most common oncogene in glioblastoma (GBM), to detect these deadly tumor cells. GBMs are characterized by diffuse infiltration into normal brain regions, and the inability to detect GBM cells renders the disease surgically incurable with a median survival of just 14.2 months. To test the sensitivity and specificity of our platform, anti-EGFR RNA aptamers were immobilized on chemically modified glass surfaces. Cells tested included primary human GBM cells expressing high levels of the wild-type EGFR, as well as genetically engineered murine glioma cells overexpressing the most common EGFR mutant (EGFRvIII lacking exons 2-7) in Ink4a/Arf-deficient astrocytes. We found that surfaces functionalized with anti-EGFR aptamers could capture both the human and murine GBM cells with high sensitivity and specificity. Our findings show how novel aptamer substrates could be used to determine whether surgical resection margins are free of tumor cells, or more widely for detecting tumor cells circulating in peripheral blood to improve early detection and/or monitoring residual disease after treatment.",
author = "Yuan Wan and Kim, {Young Tae} and Na Li and Cho, {Steve K.} and Robert Bachoo and Ellington, {Andrew D.} and Iqbal, {Samir M.}",
year = "2010",
month = "11",
day = "15",
doi = "10.1158/0008-5472.CAN-10-0568",
language = "English (US)",
volume = "70",
pages = "9371--9380",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - Surface-immobilized aptamers for cancer cell isolation and microscopic cytology

AU - Wan, Yuan

AU - Kim, Young Tae

AU - Li, Na

AU - Cho, Steve K.

AU - Bachoo, Robert

AU - Ellington, Andrew D.

AU - Iqbal, Samir M.

PY - 2010/11/15

Y1 - 2010/11/15

N2 - Exposing rare but highly malignant tumor cells that migrate from the primary tumor mass into adjacent tissue(s) or circulate in the bloodstream is critical for early detection and effective intervention(s). Here, we report on an aptamer-based strategy directed against epidermal growth factor receptor (EGFR), the most common oncogene in glioblastoma (GBM), to detect these deadly tumor cells. GBMs are characterized by diffuse infiltration into normal brain regions, and the inability to detect GBM cells renders the disease surgically incurable with a median survival of just 14.2 months. To test the sensitivity and specificity of our platform, anti-EGFR RNA aptamers were immobilized on chemically modified glass surfaces. Cells tested included primary human GBM cells expressing high levels of the wild-type EGFR, as well as genetically engineered murine glioma cells overexpressing the most common EGFR mutant (EGFRvIII lacking exons 2-7) in Ink4a/Arf-deficient astrocytes. We found that surfaces functionalized with anti-EGFR aptamers could capture both the human and murine GBM cells with high sensitivity and specificity. Our findings show how novel aptamer substrates could be used to determine whether surgical resection margins are free of tumor cells, or more widely for detecting tumor cells circulating in peripheral blood to improve early detection and/or monitoring residual disease after treatment.

AB - Exposing rare but highly malignant tumor cells that migrate from the primary tumor mass into adjacent tissue(s) or circulate in the bloodstream is critical for early detection and effective intervention(s). Here, we report on an aptamer-based strategy directed against epidermal growth factor receptor (EGFR), the most common oncogene in glioblastoma (GBM), to detect these deadly tumor cells. GBMs are characterized by diffuse infiltration into normal brain regions, and the inability to detect GBM cells renders the disease surgically incurable with a median survival of just 14.2 months. To test the sensitivity and specificity of our platform, anti-EGFR RNA aptamers were immobilized on chemically modified glass surfaces. Cells tested included primary human GBM cells expressing high levels of the wild-type EGFR, as well as genetically engineered murine glioma cells overexpressing the most common EGFR mutant (EGFRvIII lacking exons 2-7) in Ink4a/Arf-deficient astrocytes. We found that surfaces functionalized with anti-EGFR aptamers could capture both the human and murine GBM cells with high sensitivity and specificity. Our findings show how novel aptamer substrates could be used to determine whether surgical resection margins are free of tumor cells, or more widely for detecting tumor cells circulating in peripheral blood to improve early detection and/or monitoring residual disease after treatment.

UR - http://www.scopus.com/inward/record.url?scp=78549238601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78549238601&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-10-0568

DO - 10.1158/0008-5472.CAN-10-0568

M3 - Article

C2 - 21062984

AN - SCOPUS:78549238601

VL - 70

SP - 9371

EP - 9380

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 22

ER -